Ellagic Acid Protects Cardiac Arrhythmias Following Global Cerebral Ischemia/Reperfusion Model

Mahin Dianat1,2, Khojasteh Hoseiny Nejad3, Alireza Sarkaki1,2, Yaghoub Farbood1,2, Mohammad Badavi1,2, Mohammad Kazem Gharib-Naseri1

1 Physiology Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
2 Department of Physiology, Faculty of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
3 Abadan Arvand International Division, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

Abstract

Background: Cerebral ischemia/reperfusion (I/R) could increase the reactive oxidative stress in the cardiomyocytes. Also, some studies report cardiac arrhythmias following oxidative stressor such as I/R. Hence, this study was aimed to investigate the effects of ellagic acid (EA) against arrhythmias in a cerebral I/R model. Materials and Methods: Thirty-two male rats were randomly allocated into four groups: Sham (normal saline, 10 days), EA (100 mg/kg EA, 10 days), I/R (20 min ischemia followed by 30 min reperfusion, 10 days), and EA + I/R (100 mg/kg EA before I/R). In all animals, electrocardiogram (ECG) was recorded pre-ischemia and post-ischemia on the first and 11th days, respectively. Results: The I/R group showed an abnormally prolonged QTc interval after ischemia compared to the preischemia and control groups. EA administration in the EA+I/R group significantly reduced this prolonged QTc interval (P< 0.01). In the I/R group, ischemic/reperfusion resulted in a prolonged QRS complex and an elevated ST, which EA significantly prevented (P<0.01). In addition, EA significantly prevented the dramatically shortened RR interval induced by reperfusion (P<0.01). The incidence of ventricular fibrillation significantly increased in the I/R group; then it dramatically decreased following the administration of EA (P<0.0001). Conclusion: EA pretreatment repaired the adverse effects of I/R on the ECG parameters, which can be attributed to its negative chronotropic effects. EA pretreatment can prevent the cerebral I/R-induced heart arrhythmias.

[GMJ.2019;8:e1235] DOI: 10.31661/gmj.v8i0.1235

Keywords: Ellagic Acid; Ischemia/Reperfusion; Arrhythmias

Introduction

Cerebral ischemia/reperfusion (I/R) is the major cause of serious and long-term disability worldwide. Global cerebral ischemia arises when wide-spreading blood flow to the nervous system is severely disturbed, leading to a series of pathophysiological processes and the development of seizures [1]. Ischemic stroke is the most debilitating type of stroke, and global cerebral I/R has a high mortality rate of ischemia worldwide that can induce severe physical and neurological impairments and exacerbate heart failure [2]. Cardiomyo-
cyte circadian clock dysfunction is linked to the pathogenesis of heart disease in response to stresses such as I/R [3]. Approximately 80%-85% of all stroke incidents are ischemic, caused by cerebral arterial thrombosis or embolism [4]. Several studies have demonstrated that inflammation plays a fundamental role in the pathophysiology of ischemic stroke [4-6]. A free-radical reaction has been reported as an important mechanism in brain damage [7]. Not only inflammation but also oxidative stress in I/R has been recognized as a reactive oxygen species (ROS), and they are the main mediators in pathological processes [8]. The brain consumes about 20% of the body’s total oxygen; however, it only makes up 2% of the body’s total mass. Therefore, it is very sensitive to oxidative stress [9]. Moreover, the brain contains large amounts of pro-oxidative metals and polyunsaturated lipids but with a very low antioxidant capacity. Therefore, the brain is very sensitive to the ROS system that promotes damage to not only several biomolecules but also the production of some inflammatory agents participating in the neuronal death process [9, 10]. Antioxidants are known as neuroprotective factors, reducing cerebral damage in I/R. In contrast to oxidative stress, antioxidants such as polyphenolic compounds have neuroprotective effects mainly by reducing the ROS [11, 12] and inducing cardioprotective effects [13]. Ellagic acid (EA) is a natural phenolic antioxidant present in several plant foods, which can reduce oxidative stress in I/R [14]. EA can increase the antioxidant enzymes such as catalase and glutathione in brain ischemia [15], and it can have a cardioprotective effect on chemical-induced arrhythmias in stress [16]. This study was aimed at investigating the protective effects of EA pretreatment on global cerebral I/R induced-cardiovascular injuries. The electrocardiogram (ECG) parameters were assessed comparatively pre-ischemia and postischemia in each group of rats, and the changes in the parameters were compared among the groups.

Materials and Methods

Animals
This was an experimental animal study conducted on 32 adult male Wistar rats (250-300 g) in the physiology department of Ahvaz Jundishapur University of Medical Sciences (AJUMS), Ahvaz, Iran. The rats were obtained from AJUMS’s animal house and were housed in four laboratory cages and maintained under the following conditions: a 12/12-hour light/dark cycle, sufficient access to food and water, constant temperature of 22±2 oC, and 50% humidity. They were maintained under these conditions for 14 days of acclimation. All the protocols were approved by the animal ethics committee of AJUMS (registry code: B-9348) and were in complete accordance with the National Academy of Sciences (eighth edition) guidelines.

Global Cerebral I/R Induction
Global cerebral I/R induction was completed based on the procedures that were completely described in previous studies by Pulsinelli and Brierley [17], Hoseiny Nejad et al. [18], and Xue et al. [14]. After anesthesia, the rats underwent a temporary forebrain global ischemia [17]. On the second day, after 20 min of ischemia phase, reperfusion was started for 30 min with the opening of the carotid microclamps. Similar procedures were performed for the sham and EA groups without global ischemia [14]. Serum samples were collected from blood samples obtained from the right ventricle through coagulation processes and 10-min centrifuging at 4000 rpm. Serum samples were then stored at -80°C.

Study Design
The animals were randomly allocated into four groups (n=8 per group):
1. The Sham or negative control group received 100 mg/kg normal saline as a solvent for EA by oral gavage for 10 days.
2. The EA or positive group received 100 mg/kg of EA by oral gavage for 10 days.
3. The I/R group received the 1.5 ml/kg solvent (oral gavage, 10 days) and then underwent global cerebral I/R.
4. The EA+I/R group received 100 mg/kg of EA by oral gavage for 10 days and underwent global cerebral I/R.

Recording ECG
Fifteen minutes after the anesthesia, a bipolar limb lead II electrocardiogram was recorded.
to detect heart rates (HR) and to assess the chronotropic effect, QTC interval (to assess the developing risk of ventricular arrhythmias), QRS voltage (to assess the inotropic effect), R-R interval (to assess the possibility of premature ventricular contractions), ST elevation, and ventricular fibrillation (VF) incidence (to assess the possibility of cardiac arrest). The ECG was recorded on the first and 11th days (before and after ischemia) by Bio-Amp and monitored using a Power Lab system (AD-Instruments, Australia) [16]. Bazett’s formula (QTc=QT/RR1/2) is widely used to calculate the corrected QT interval for human HR. The QT interval is related to the HR changes; short QT indicates an increased heart rate [19]. All chemicals were purchased from Kimia-Zist Azma Company (Tehran, Iran).

Statistical Analysis
The ECG variables were analyzed using a paired t-test and one-way analysis of variance (ANOVA), followed by the least significant difference (LSD) as a posthoc test for multiple comparisons. A P-value less than 0.05 was set at significant statistical.

Results

EA Effects On QTC Interval After Ischemia
Comparison of QTc values before and after the ischemia in this study’s groups showed a significant prolongation in each group (Table-1). Moreover, QTc values caused a significant difference in the EA+I/R rats compared with the I/R rats (P<0.05; F-value [3, 4]: 6). An abnormally prolonged QTc interval was observed after the ischemia in the I/R group compared with the preischemia condition in the control group (P<0.001; F-value [3, 4]: 11) but was significantly reduced by EA pre-treatment in the EA+I/R rats.

Effects of EA On ST Segment, R-R Interval, and QRS Duration Global Cerebral I/R Model
Comparison of the ST segment, R-R interval, and QRS duration induced by global cerebral I/R, showed significant differences in the studied groups (Table-2). Respectively, a prolonged QRS duration, a short R-R interval, and an elevated ST were observed in I/R and EA+I/R rats compared to the control groups. In addition, these changes caused a significant difference in EA+I/R rats compared to I/R rats (P<0.05; F-value [2, 3]: 6; Table-2).

Effects of EA On the Incidence of VF Induced by Global Cerebral I/R
Comparison of the incidence of VF in various groups showed a significant increase in other groups compared to the control groups. There was not VF incidence in sham and EA groups, but it was 25% and 75% for I/R and EA+I/R, respectively, which showed a significant difference compared to the control groups (P=0.0005). Moreover, EA+I/R rats showed a reduced VF incident compared with the I/R rats (P< 0.01).

Table 1. Comparisons of QTc Values Before and After Ischemia Among Studied Groups. Values Are Expressed as Mean ± SEM.

| Groups   | QTc before I/R (milliseconds) | QTc after I/R (milliseconds) | P-value | F-value (3, 4) |
|----------|-------------------------------|-----------------------------|---------|---------------|
| Sham     | 84.71 ± 2.5                   | 84.5 ± 3                    | 0.57    | 0.76          |
| EA       | 88.42 ± 2.5                   | 87.28 ± 2.5                 | 0.56    | 0.78          |
| I/R      | 86.28 ± 1.5                   | 130 ± 2                     | 0.0007  | 11            |
| EA+I/R   | 87.14 ± 3.5                   | 98.14 ± 3.5                 | 0.01    | 6             |

EA: Ellagic acid; I/R: Ischemia/reperfusion
Discussion

The results of this study demonstrated significant abnormal alterations in ECG variables from the I/R model, including a prolonged QTc interval, a prolonged QRS duration, a short R-R interval, an elevated ST, and an increased VF incidence in the experimental models. The EA pretreatment significantly prevented these I/R-induced abnormal changes of ECG parameters in I/R and EA+I/R groups. Boyuk et al. (2011) reported a significant therapeutic effect of EA on intestinal I/R injury in rat’s lung tissue [20]. Meerson and Belkina (1986) showed the protective effect of ionol as an antioxidant on ischemia, arrhythmias, and heart fibrillation in the male rats [21]. They reported that reperfusion could induce more severe ventricular arrhythmias than ischemia. Other types of arrhythmias, tachycardia, and extrasystole also occurred during I/R. The pre-administration of ionol eliminated VF during I/R. Ionol significantly reduced the incidence of tachycardia and extrasystole. The present study’s findings confirm the results of Meselson and Belkina’s study. EA, as an antioxidant agent like ionol, could significantly reduce VF incidence and arrhythmias during I/R. Seeram et al. (2005) reported EA’s antioxidant and antiproliferative properties in some in-vitro and small-animal models [22]. EA, as an antiproliferative antioxidant, could directly inhibit some carcinogens’ DNA binding [23, 24]. Kannan and Quine (2011) investigated EA’s cardioprotective effects on the myocardial infarction and reported that EA reduced the lipid peroxidation and levels of biochemical markers. Moreover, EA significantly increased antioxidant activity and content in the isoproterenol groups, which subsequently prevented oxidative stress in myocardial infarction [25]. In their follow-up study, Kannan and Quine (2013) demonstrated EA’s inhibitory effects on arrhythmias, hyperlipidemia, and hypertrophy during myocardial infarction in rats [26]. Despite many studies conducted on EA’s antioxidant, pharmacodynamics, and cardioprotective effects [27, 28], only a few of them have investigated the EA pretreatment’s effects on the global cerebral I/R model. One of the limitations of our study was that the laboratory biomarkers related to the global cerebral I/R were not evaluated.

Conclusion

EA pretreatment could have beneficial effects on global cerebral I/R by altering I/R-induced adverse effects on ECG parameters. EA showed positive inotropic and negative chronotropic effects. In addition, EA pretreatment prevented the global cerebral I/R-induced heart arrhythmias.

Conflict of Interest

The authors have no conflict of interest to declare.
Ellagic Acid and Cardiac Arrhythmias Following Global Cerebral I/R

Dianat M, et al.

References

1. Mumby DG, Wood ER, Duva CA, Kornecook TJ, Pinel JPJ, Phillips AG. Ischemia-induced object-recognition deficits in rats are attenuated by hippocampal ablation before or soon after ischemia. Behav Neurosci. 1996;110(2):266-81.
2. Schweitzer S, Meisel A, Marschenz S. Epigenetic mechanisms in cerebral ischemia. J Cerebr Blood F Met. 2013;33(9):1335-46.
3. Durgan DJ, Young ME. The cardiomyocyte circadian clock: emerging roles in health and disease. Circ Res. 2010;106(4):647-58.
4. Tobin MK, Bonds JA, Minshall RD, Pelligrino DA, Testai FD, Lazarov O. Neurogenesis and inflammation after ischemic stroke: what is known and where we go from here. J Cerebr Blood F Met. 2014;34(10):1573–84.
5. Jin R, Yang G, Li G. Inflammatory mechanisms in ischemic stroke: role of inflammatory cells. J Leukocyte Biol. 2010;87(5):779–89.
6. Lakhan SE, Kirchgessner A, Hofer M. Inflammatory mechanisms in ischemic stroke: therapeutic approaches. J Transl Med. 2009;7(97):1-11.
7. Paciaroni M, Caso V, Agnelli G. The concept of ischemic penumbra in acute stroke and therapeutic opportunities. Eur Neurol. 2009;61(6):321–30.
8. Schaller B, Graf R. Cerebral ischemia and reperfusion: The pathophysiological concept as a basis for clinical therapy. J Cerebr Blood F Met. 2004;24(4):351–71.
9. Halliwell B. Reactive oxygen species and the central nervous system. J Neurochem. 1992;59(5):1609–23.
10. Trastman RJ, Kirsch JR, Koehler RC. Oxygen radical mechanisms of brain injury following ischemia and reperfusion. J Appl Physiol. 1991;71(4):1185–95.
11. Curin Y, Ritz MF, Andriantsitohaina R. Cellular mechanisms of the protective effect of polyphenols on the neurovascular unit in strokes. Cardiovasc Hematol Agents Med Chem. 2006;4(4):277–88.
12. Kannan MM, Quine SD. Ellagic acid ameliorates isoproterenol induced oxidative stress: Evidence from electrocardiologival, biochemical and histological study. Eur J Pharmacol. 2011;659(1):45-52.
13. Dianat M, Veisi A, Ahangarpour A, Fathi Moghaddam H. The effect of hydro-alcoholic celery (Apiumgraveolens) leaf extract on cardiovascular parameters and lipid profile in animal model of hypertension induced by fructose. Avicenna J Phytomed. 2015;5(3):203-09.
14. Xue R, He J, Wang N, Yao F, Lv J, Wu G. Relationship between transmembrane signal transduction pathway and DNA repair and the mechanism after global cerebral ischemia-reperfusion in rats. Neurosci Bull. 2009;25(3):115-21.
15. Pang X, Li T, Feng L, Zhao J, Zhang X, Liu J. Ellagic acid-induced thrombotic focal cerebral ischemic model in rats. J Pharmacol Toxicol Methods. 2014;69(3):217-22.
16. Dianat M, Amini N, Badavi M, Farbood Y. Ellagic acid improved arrhythmias induced by CaCL2 in the rat stress model. Avicenna J Phytomed. 2015;5(2):120-27.
17. Pulsinelli W, Brierley J. A new model of bilateral hemispheric ischemia in the unanesthetized rat. Stroke. 1979;10(3):267–72.
18. Hoseiny Nejad K, Dianat M, Sarkaki A, Gharib Naseri MK, Badavi M, Farbood Y. Ellagic acid improves electrocardiogram waves and blood pressure against global cerebral ischemia rat experimental models. Electronic Physicin. 2015;7(4):1153-62.
19. Bazett HC. An Analysis of the time-relations of electrocardiograms. Heart. 1997;2(2):177-94.
20. Boyuk A, Onder A, Kapan M, Gumuş M, Firat U, Başaral MK. Ellagic acid ameliorates lung injury after intestinal ischemia-reperfusion. Pharmacogn Mag. 2011;7(27):224–28.
21. Meerson FZ, Belkina LM. Prevention of ischemic and re-oxygenation arrhythmias and heart fibrillation using the antioxidant ionol. Biull Eksp Biol Med. 1986;101(6):662-64.
22. Seeram NP, Adams LS, Henning SM, Niu Y, Zhang Y, Nair MG, Heber D. In vitro antiproliferative, apoptotic and antioxidant activities of punicalagin, ellagic acid and a total pomegranate tannin extract are enhanced in combination with other polyphenols as found in pomegranate juice. J Nutr Biochem. 2005;16(6):360–67.
23. Mandal S, Stoner GD. Inhibition of N-nitrosobenzylmethyamine-induced esophageal tumorigenesis in rats by ellagic acid. Carcinogenesis. 1990;11(1):55–61.
24. Babcock T, Stoner D. Ellagic acid toxicity and interaction with benzo [a] pyrene and benzo [a] pyrene 7, 8-dihydrodiol in human bronchial epithelial cells. Cell Biol Toxicol. 1986;2(1):53–62.
25. Kannan MM, Quine SD. Pharmacodynamics of ellagic acid on cardiac troponin-T, lysosomal enzymes and membrane bound ATPases: Mechanistic clues from biochemical, cytokine and in vitro studies. Chem biol interact. 2011;193(2):154-61.
26. Kannan MM, Quine SD. Ellagic acid inhibits cardiac arrhythmias, hypertrophy and hyperlipidemia during myocardial infarction in rats. Metabolism. 2013;62(1):52-61.
27. Kilic I, Yesiloglu Y, Bayrak Y. Spectroscopic studies on the antioxidant activity of ellagic acid. Spectrochim Acta A Mol Biomol Spectrosc. 2014;130:447-52.
28. Warpe VS, Mali VR, Bodhankar SL, Mahadik KR. Cardioprotective effect of ellagic acid on doxorubicin induced cardiotoxicity in wistar rats. Journal of acute medicine. 2015;5(1):1–8.